Department of Intensive Care 4131, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.
Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Intensive Care Med. 2016 Nov;42(11):1685-1694. doi: 10.1007/s00134-016-4437-x. Epub 2016 Sep 30.
We assessed the predefined long-term outcomes in patients randomised in the Transfusion Requirements in Septic Shock (TRISS) trial.
In 32 Scandinavian ICUs, we randomised 1005 patients with septic shock and haemoglobin of 9 g/dl or less to receive single units of leuko-reduced red cells when haemoglobin level was 7 g/dl or less (lower threshold) or 9 g/dl or less (higher threshold) during ICU stay. We assessed mortality rates 1 year after randomisation and again in all patients at time of longest follow-up in the intention-to-treat population (n = 998) and health-related quality of life (HRQoL) 1 year after randomisation in the Danish patients only (n = 777).
Mortality rates in the lower- versus higher-threshold group at 1 year were 53.5 % (268/501 patients) versus 54.6 % (271/496) [relative risk 0.97; 95 % confidence interval (CI) 0.85-1.09; P = 0.62]; at longest follow-up (median 21 months), they were 56.7 % (284/501) versus 61.0 % (302/495) (hazard ratio 0.88; 95 % CI 0.75-1.03; P = 0.12). We obtained HRQoL data at 1 year in 629 of the 777 (81 %) Danish patients, and mean differences between the lower- and higher-threshold group in scores of physical HRQoL were 0.4 (95 % CI -2.4 to 3.1; P = 0.79) and in mental HRQoL 0.5 (95 % CI -3.1 to 4.0; P = 0.79).
Long-term mortality rates and HRQoL did not differ in patients with septic shock and anaemia who were transfused at a haemoglobin threshold of 7 g/dl versus a threshold of 9 g/dl. We may reject a more than 3 % increased hazard of death in the lower- versus higher-threshold group at the time of longest follow-up.
我们评估了接受输血需求在脓毒症休克(TRISS)试验随机分组的患者的预先设定的长期结局。
在 32 家斯堪的纳维亚 ICU 中,我们将 1005 例脓毒症休克且血红蛋白水平<9g/dl 的患者随机分为两组,当血红蛋白水平<7g/dl 时(较低阈值)或<9g/dl 时(较高阈值)给予单个去白细胞的红细胞单位。我们评估了随机分组后 1 年以及意向治疗人群中所有患者最长随访时间(n=998)时的死亡率,并在丹麦患者中仅评估了随机分组后 1 年的健康相关生活质量(HRQoL)(n=777)。
在较低阈值组与较高阈值组中,1 年的死亡率分别为 53.5%(268/501 例)和 54.6%(271/496 例)[相对风险 0.97;95%置信区间(CI)0.85-1.09;P=0.62];在最长随访时间(中位数 21 个月)时,死亡率分别为 56.7%(284/501 例)和 61.0%(302/495 例)(风险比 0.88;95%CI 0.75-1.03;P=0.12)。在 777 例丹麦患者中,我们获得了 1 年时的 HRQoL 数据,在较低阈值组与较高阈值组之间,身体 HRQoL 评分的平均差值为 0.4(95%CI-2.4 至 3.1;P=0.79),心理 HRQoL 评分的平均差值为 0.5(95%CI-3.1 至 4.0;P=0.79)。
在血红蛋白阈值为 7g/dl 与 9g/dl 之间接受输血的脓毒症休克伴贫血患者中,长期死亡率和 HRQoL 无差异。我们可以排除在最长随访时间时较低阈值组与较高阈值组之间的死亡风险增加超过 3%的可能性。